HomeInsightsStock Comparison

Alembic Pharmaceuticals Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Alembic Pharmaceuticals Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Last Updated on: May 10, 2025

Key Highlights

  • The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 901.7 as of 09 May 15:30.
  • The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 12.1 on March 2020 to 31.4 on March 2024 . This represents a CAGR of 21.01% over 5 yearsThe P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 22.5 on March 2020 to 40.6 on March 2024 . This represents a CAGR of 12.53% over 5 years.
  • The Market Cap of Alembic Pharmaceuticals Ltd changed from ₹ 10059 crore on March 2020 to ₹ 19309 crore on March 2024 . This represents a CAGR of 13.93% over 5 yearsThe Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 84504 crore on March 2020 to ₹ 388812 crore on March 2024 . This represents a CAGR of 35.70% over 5 years.
  • The revenue of Alembic Pharmaceuticals Ltd for the Mar '25 is ₹ 1783 crore as compare to the Dec '24 revenue of ₹ 1702 crore. This represent the growth of 4.77% The revenue of Sun Pharmaceutical Industries Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 14141 crore. This represent the decline of -100%.
  • The ebitda of Alembic Pharmaceuticals Ltd for the Mar '25 is ₹ 285.46 crore as compare to the Dec '24 ebitda of ₹ 270.08 crore. This represent the growth of 5.69% The ebitda of Sun Pharmaceutical Industries Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 4158 crore. This represent the decline of -100%.
  • The net profit of Alembic Pharmaceuticals Ltd changed from ₹ 120.6 crore to ₹ 156.63 crore over 8 quarters. This represents a CAGR of 13.96% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2013 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% .
  • The Dividend Payout of Alembic Pharmaceuticals Ltd changed from 19.45 % on March 2020 to 32.44 % on March 2024 . This represents a CAGR of 10.77% over 5 yearsThe Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 29.89 % on March 2020 to 113.33 % on March 2024 . This represents a CAGR of 30.55% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alembic Pharmaceuticals Ltd

  • Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world.
  • The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Ltd was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in pharmaceuticals business.
  • As per the scheme of arrangement, the 'Pharmaceutical Undertaking' of the Alembic Ltd was demerged and transferred to the company with effect from appointed date, April 1, 2010. In April 15, 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

About Sun Pharmaceuticals Industries Ltd

  • Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
  • The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
  • It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
  • The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

Alembic Pharmaceuticals Ltd News Hub

News

Board of Alembic Pharmaceuticals recommends final dividend

Alembic Pharmaceuticals announced that the Board of Directors of the Company at its meetin...

Read more

06 May 2025 14:39

News

Alembic Pharma slips after Q4 PAT drops 12% YoY to Rs 157 cr

Revenue from operations grew 16.66% year on year (YoY) to Rs 1,769.64 crore in the quarter...

Read more

06 May 2025 15:26

News

Alembic Pharmaceuticals receives USFDA final approval for Ticagrelor Tablets

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from...

Read more

02 May 2025 14:55

News

Alembic Pharma gains after receiving EIR from USFDA for Panelav facility

The company announced in an exchange filing that the EIR pertains to an inspection conduct...

Read more

30 Apr 2025 13:17

News

Alembic Pharmaceuticals commissions new facility at Pithampur, Madhya Pradesh

Alembic Pharmaceuticals has commissioned a new manufacturing facility located at Pithampur...

Read more

26 Apr 2025 14:24

News

Alembic Pharmaceuticals to conduct board meeting

Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6 ...

Read more

19 Apr 2025 10:36

Sun Pharmaceutical Industries Ltd News Hub

News

Sun Pharma and Israel-based Moebius Medical publish two articles on MM-II

Sun Pharmaceutical Industries and Israel-based Moebius Medical announced today the publica...

Read more

24 Apr 2025 09:12

News

Sun Pharmaceutical launches Fexuprazan tablets 40 mg in India

Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the bra...

Read more

07 Apr 2025 09:07

News

Sun Pharma launches Fexuprazan tablets 40 mg in India

The drug, available in 40 mg tablets, is approved as a new treatment for adults with erosi...

Read more

07 Apr 2025 10:23

News

Sun Pharma completes acquisition of Antibe Therapeutics Inc., Canada

Sun Pharmaceutical Industries has completed 100% acquisition of Antibe Therapeutics Inc., ...

Read more

18 Mar 2025 15:01

News

Sun Pharma gains as arm acquires Antibe Therapeutics for $4.5 Million

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty...

Read more

18 Mar 2025 12:53

News

Sun Pharmaceuticals Industries Ltd soars 0.96%, gains for fifth straight session

Sun Pharmaceuticals Industries Ltd rose for a fifth straight session today. The stock is q...

Read more

17 Mar 2025 13:00

SWOT Analysis Of Sun Pharmaceutical Industries Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Alembic Pharmaceuticals Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Sun Pharmaceuticals Industries Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alembic Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alembic Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd

Which company has a larger market capitalization, Alembic Pharmaceuticals Ltd or Sun Pharmaceutical Industries Ltd?

Market cap of Alembic Pharmaceuticals Ltd is 17,724 Cr while Market cap of Sun Pharmaceutical Industries Ltd is 418,647 Cr

What are the key factors driving the stock performance of Alembic Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd?

The stock performance of Alembic Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alembic Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd?

As of May 10, 2025, the Alembic Pharmaceuticals Ltd stock price is INR ₹901.7. On the other hand, Sun Pharmaceutical Industries Ltd stock price is INR ₹1744.85.

How do dividend payouts of Alembic Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd compare?

To compare the dividend payouts of Alembic Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions